Clinical Ink, Inc.

Clinical Ink, Inc. is a US-based company specializing in innovative clinical trial solutions through its advanced eSource platform, enhancing data collection and patient engagement in clinical research. Clinical Ink, Inc. provides clinical trial solutions focusing on eSource technology, founded in 2007 and headquartered in Winston-Salem, US.

The company has undergone successful rounds of funding, including a Series C round where it raised USD 5. 40 mn in December 2020 from Clayton Associates. It has participated in six total deals to date. Clinical Ink specializes in a comprehensive suite of clinical trial solutions centered around its eSource platform, which integrates Direct Data Capture (DDC) technology and electronic Clinical Outcome Assessments (eCOA).

This ecosystem unifies incoming data from diverse sources into a single platform, enhancing the efficiency and quality of clinical trial data across various phases and therapeutic areas, including neurology, infectious diseases, immunology, and oncology. Their services facilitate decentralized clinical trials, allowing direct data collection from patients and improving engagement. Clinical Ink serves pharmaceutical companies and Contract Research Organizations (CROs) in North America and Europe, aiming to streamline trial procedures and optimize data collection methodologies. Clinical Ink's revenue model is built on B2B transactions with pharmaceutical companies and CROs, typically through subscription agreements or project-based contracts for services such as eCOA, DDC, and telehealth solutions.

Their flagship offerings include the eLAS® Suite for lupus clinical trials and TrialLens™, a dashboard managing eCOA and connected device trials. Pricing structures are based on the scope of services, contract duration, and specific technologies deployed, ensuring flexibility for diverse client needs in clinical research. Clinical Ink plans to develop new products and enhance its eSource platform to meet evolving client needs. The company targets expansion into new markets across Europe by the end of 2023.

The recent Series C funding of USD 5. 40 mn will support these initiatives, focusing on product innovation and market penetration. In December 2020, McKesson Ventures made a strategic investment in Clinical Ink, furthering its growth prospects.